Becton, Dickinson and Company $BDX Shares Bought by Cacti Asset Management LLC

Cacti Asset Management LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 180,271 shares of the medical instruments supplier’s stock after acquiring an additional 1,500 shares during the period. Becton, Dickinson and Company comprises about 2.2% of Cacti Asset Management LLC’s holdings, making the stock its 16th largest holding. Cacti Asset Management LLC owned approximately 0.06% of Becton, Dickinson and Company worth $30,801,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. REAP Financial Group LLC increased its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Finally, Cornerstone Planning Group LLC raised its holdings in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $187.23 on Friday. The stock’s 50 day moving average price is $186.46 and its 200-day moving average price is $191.73. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $53.66 billion, a PE ratio of 33.67, a PEG ratio of 1.42 and a beta of 0.27. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the business posted $3.50 EPS. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock worth $551,536 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on BDX. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Barclays dropped their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a report on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.